Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Marion Merrell Dow's Cardizem Q.D.

Executive Summary

Once-a-day version of calcium channel blocker diltiazem for treatment of hypertension will be the subject of FDA's Cardiovascular and Renal Drugs Advisory Committee meeting on March 14. The panel also will consider labeling implications of left ventricular hypertrophy. On March 15, the committee will discuss labeling revisions for Bristol-Myers Squibb's anti-arrhythmic Enkaid (encainide). The meeting begins both days at 9 a.m. in the Masur Auditorium on the NIH campus.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS018765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel